Utilization Trends and Concentration Ratio of Korean Medicine: Based on the National Health Insurance Data
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives: Although Korean Medicine (KM) subsidized by the National Health Insurance (NHI) has been used for a long time, there has been no active analysis using claims data . Therefore, the purpose of this study was to examine the NHI KM utilization trend using NHI statistics and to measure the level of market concentration by year. Methods: By restructuring the contents of NHI Statistics for Pharmaceuticals for 2010-2019, the claim cases, costs, and annual growth rates of KM were demonstrated by year, sex, age group, region, therapeutic group, and KM treatment. The proportion of highly used k treatments in cost was calculated as the concentration ratio (CR) k and its trend by year was investigated. Results: In 2019, the NHI cost on KM amounted to ₩38.2 billion KRW, increasing by 11.6% per year on average in 2010-2019. Notably, KM was used more frequently among women and patients aged ≥ 65 years, and the mixed formulation accounted for 95% of the total cost of KM. The CR of the simple formulation increased rapidly, whereas that of the mixed formulation remained constant. In 2019, three simple formulation treatments— peony, licorice, and ginseng— accounted for 93.8% of the total cost for KM (CR3 = 93.8%). Conclusion: NHI KM is rapidly increasing. Investigating the CR of KM confirmed that KM prescriptions have been concentrated in small numbers over the past 10 years.
Abstract
Objectives: Although Korean Medicine (KM) subsidized by the National Health Insurance (NHI) has been used for a long time, there has been no active analysis using claims data . Therefore, the purpose of this study was to examine the NHI KM utilization trend using NHI statistics and to measure the level of market concentration by year. Methods: By restructuring the contents of NHI Statistics for Pharmaceuticals for 2010-2019, the claim cases, costs, and annual growth rates of KM were demonstrated by year, sex, age group, region, therapeutic group, and KM treatment. The proportion of highly used k treatments in cost was calculated as the concentration ratio (CR) k and its trend by year was investigated. Results: In 2019, the NHI cost on KM amounted to ₩38.2 billion KRW, increasing by 11.6% per year on average in 2010-2019. Notably, KM was used more frequently among women and patients aged ≥ 65 years, and the mixed formulation accounted for 95% of the total cost of KM. The CR of the simple formulation increased rapidly, whereas that of the mixed formulation remained constant. In 2019, three simple formulation treatments— peony, licorice, and ginseng— accounted for 93.8% of the total cost for KM (CR3 = 93.8%). Conclusion: NHI KM is rapidly increasing. Investigating the CR of KM confirmed that KM prescriptions have been concentrated in small numbers over the past 10 years.
참고문헌 (11)
- "Pharmaceutical Affairs Act" (2021)[URL]
- "Notice No.2020-338 List of Herbal Medicinal Preparations Covered with National Health Insurance and Upper Limit Amount Table" (2020)[URL]
- "A Report for the Rational Improvement of the Standard Prescription of Herbal Medicine" (2014)[URL]
- 이인, "와파린과 상호작용하는 한약재에 대한 고찰", 대한한방내과학회지, 33(2), pp.160~171 (2012), 대한한방내과학회
- 김동현, "골관절염 환자의 한약 양약 투여 현황 및 안전성 연구", 대한한방내과학회지, 39(2), pp.97~106 (2018), 대한한방내과학회
- 김윤경, "한약제제 보험급여 주상병과 처방분석", 대한본초학회지, 21(4), pp.1~10 (2006), 대한본초학회
- 강소현, "최근 5개년 (2013~2017)간 기관지확장증(J47) 환자에게 처방한 급여한약제제 현황 분석 – 건강보험청구자료 중심으로", 대한예방한의학회지, 23(3), pp.1~12 (2019), 대한예방한의학회[DOI]
- 권용찬, "한방건강보험 약제 투약 실태 및 활성화 방안 연구", 대한본초학회지, 27(2), pp.1~16 (2012), 대한본초학회
- 김경한, "한의사의 한약제제 인식도와 만족도", 대한예방한의학회지, 21(2), pp.15~22 (2017), 대한예방한의학회[DOI]
- "National Health Insurance Drug Statistics 2019" (2020)[URL]
- 허재헌, "보험약가, 의약품 시장구조와 기업행동", 박사, 보건정책관리학, pp.2011